Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages between 18 and 70;~2. Weighs between 40 \~ 100 kg, and BMI ≥ 18 kg/m2;~3. Must have a clinical diagnosis of CAP~4. Chest X-ray shows new or persist/progressive infiltrates~5. If female, non-lactating and at no risk or pregnancy (post-menopausal or must use adequate birth control)~6. The patient is able to take the drug orally.~Exclusion Criteria:~1. Patients with CAP that, in the investigator's judgment, is severe enough to require hospitalization for intravenous antibiotic therapy and/or supplemental oxygen therapy with ICU support~2. Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary tuberculosis or infection with other mycobacteria or fungi, known bronchial obstruction, a history of post-obstructive pneumonia, other confounding respiratory diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess, empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory infection (chronic obstructive pulmonary disease \[COPD\] is not exclusionary)~3. Clinically significant conduction or other abnormality on 12-lead ECG, or QTc interval~4. Potassium is \< 3.5 mmol/L~5. Any known disease that seriously affect the immune system~6. Active hepatitis or decompensated cirrhosis;~7. Have used quinolones or fluoroquinolones within 14 days before enrollment~8. Patients who are being or will be on a long-term medication of steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nemonoxacin 500 mg (Type: EXPERIMENTAL): None
- Levofloxacin 500 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).